At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pharmacokinetics of Infliximab and Tumor Necrosis Factor Concentrations in Serum, Stool, and Colonic Mucosa in Acute Severe Ulcerative Colitis
In Brief
An observational study evaluating Infliximab for Ulcerative Colitis. Active but no longer recruiting, targeting 18 participants across 3 sites in 2 countries.
Signals
Detailed Summary
This is an open-label, prospective, observational study with the primary objective to characterize the pharmacokinetics of infliximab in patients with Acute Severe Ulcerative Colitis.
Study Details
Timeline
Arms & Interventions
Patients with Acute Severe Ulcerative Colitis who are either a) biologic-naïve or b) biologic-experienced without a known history of anti-infliximab antibodies requiring infliximab infusion therapy as a part of standard of care.
Interventions
Patients will receive infliximab at the discretion of their physician as part of standard of care.